BTI vs BUD

BTI's deterministic health score is stable with a Piotroski F-Score of 6/9, indicating moderate financial strength, though the absence of an Altman Z-Score limits distress risk assessment. The stock trades significantly above its Graham Number of $34.30 at $59.16, reflecting a rich valuation despite declining revenue and a concerning 168.95% dividend payout ratio. Strong operating margins and a high dividend yield provide support, but deteriorating growth and weak technicals (10/100) offset these advantages. Analysts recommend a buy with a near-current target price, suggesting limited upside.

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant operational and profitability concerns. Despite this, the stock trades above its Graham Number of $52.90 at $69.88, supported by a bullish analyst recommendation and strong recent price performance. Earnings growth has collapsed year-over-year (-48.6%), yet the company consistently beats estimates, showing some earnings quality. Profit margins and cash flow generation remain solid, but missing key financial health metrics like ROE, ROA, and Altman Z-Score limits confidence in stability. The dividend is sustainable with a 37.5% payout ratio, but insider sentiment and technical trend are weak.